← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	1,045	-41	-4%	$41.7B
2	2 Thermo Fisher Scientific TMO $249B	1,045	-11	-1%	$55.5B
3	3 Novartis NVS $279B	877	-2	-0.2%	$18.7B
4	4 Agilent Technologies A $49.1B	557	-20	-3%	$13.2B
5	5 Regeneron Pharmaceuticals REGN $80.1B	555	+13	+2%	$29.6B
6	6 Illumina ILMN $41B	553	+27	+5%	$25.3B
7	7 Revvity RVTY $17B	324	-24	-7%	$5.62B
8	8 Charles River Laboratories CRL $14.4B	284	-2	-0.7%	$3.85B
9	9 Ionis Pharmaceuticals IONS $7.1B	283	0	0%	$3.94B
10	10 Alnylam Pharmaceuticals ALNY $30B	260	+11	+4%	$5.25B
11	11 Myriad Genetics MYGN $397M	224	-29	-11%	$1.7B
12	12 Bruker BRKR $8.47B	210	-26	-11%	$2.5B
13	13 DELISTED CATALENT, INC. CTLT	202	+16	+9%	$3.31B
14	14 DELISTED bluebird bio BLUE	201	+24	+14%	$3.02B
15	ISEE 15 DELISTED IVERIC bio, Inc. Common Stock ISEE	192	+10	+5%	$1.59B
16	16 Sarepta Therapeutics SRPT $1.78B	188	+40	+27%	$2.6B
17	17 Ultragenyx Pharmaceutical RARE $1.47B	174	+12	+7%	$2.8B
18	18 Precigen PGEN $2.64B	169	0	0%	$2.82B
19	19 Azenta AZTA $1.63B	158	+6	+4%	$876M
20	20 Pacific Biosciences PACB $619M	128	-13	-9%	$583M
21	21 DELISTED SANGAMO THERAPEUTICS INC SGMO	125	-11	-8%	$204M
22	22 PTC Therapeutics PTCT $4.98B	116	-2	-2%	$409M
23	NSTG 23 DELISTED NanoString Technologies, Inc. NSTG	101	+16	+19%	$348M
24	24 Standard BioTools LAB $248M	98	+1	+1%	$218M
25	25 Arrowhead Research ARWR $8.25B	97	+9	+10%	$222M